Atyr Pharma Inc (LIFE) SEC Filing 8-K Material Event for the period ending Friday, June 28, 2019

Atyr Pharma Inc

CIK: 1518621 Ticker: LIFE

View differences made from one to another to evaluate Atyr Pharma Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Atyr Pharma Inc.


Assess how Atyr Pharma Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Atyr Pharma Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Atyr Pharma Inc provided additional information to their SEC Filing as exhibits

Ticker: LIFE
CIK: 1339970
Form Type: 8-K Corporate News
Accession Number: 0001564590-19-024064
Submitted to the SEC: Fri Jun 28 2019 4:15:36 PM EST
Accepted by the SEC: Fri Jun 28 2019
Period: Friday, June 28, 2019
Industry: Biological Products No Disgnostic Substances
  1. Bylaw Change
  2. Financial Exhibit
  3. Other Events
  4. Security Holders Change

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: